ライフサイエンスコーパス: valacyclovir

1 iation of effective antiviral treatment with valacyclovir.

2 ing while receiving pritelivir compared with valacyclovir.

3 hich allowed etiological treatment with oral valacyclovir.

4 y, which was treated with corticosteroid and valacyclovir.

5 l-3-HPG exhibited comparable permeability to valacyclovir.

6 atients with herpes zoster were treated with valacyclovir.

7 ravenous acyclovir, she was switched to oral valacyclovir.

8 doses of 100 mg of pritelivir with 500 mg of valacyclovir.

9 rred after discontinuation of treatment with valacyclovir.

10 x virus reactivation (n = 932); acyclovir or valacyclovir 1 year (n = 1117); or acyclovir/valacyclovi

11 acyclovir (500 mg twice daily), or high-dose valacyclovir (1 g twice daily) in this 18-week trial.

12 14 of the susceptible partners who received valacyclovir (1.9 percent), as compared with 27 (3.6 per

13 the safety and efficacy of an oral dosage of valacyclovir, 1 g TID versus 2 g TID, for the treatment

14 Oral valacyclovir, 1 g twice daily, was administered to 65 ou

15 Eight patients received oral valacyclovir 2 g tid (Valtrex, GlaxoSmithKline) and one

16 tly, patients received two 14-day courses of valacyclovir (2 g orally, three times per day) at 1-3 da

17 r 1 year after initial treatment with 1 g of valacyclovir 3 times daily for 1 week in a prospective,

18 A dosage of 1 g of valacyclovir 3 times per day (TID) for 7 days has alread

19 mg as a single dose), placebo for 3 days, or valacyclovir (500 mg twice daily for 3 days).

20 To determine the efficacy and safety of valacyclovir (500 mg twice daily) for the suppression of

21 mized 1:1:1 to 12 weeks of placebo, low-dose valacyclovir (500 mg twice daily), or high-dose valacycl

22 1200 mg; HR, 1.72; P = .007), and 113.9 with valacyclovir (500 mg twice daily; HR, 1.42; P = .077), i

23 yclovir daily or with a combination of daily valacyclovir (500 mg) plus twice-daily doses of aspirin

24 ex virus type 2 (HSV-2)-suppressive therapy (valacyclovir, 500 mg twice daily, or placebo for 8 weeks

25 Treatment of infected mice with valacyclovir, a potent inhibitor of HSV-1 replication, p

26 articipants with genital HSV-2 received oral valacyclovir, acyclovir, and matching placebo in random

27 aneous specimens obtained during placebo and valacyclovir administration, respectively (P<.001).

28 Treatment with valacyclovir also decreased the rates of CMV viremia and

29 ession of viral replication is not complete, valacyclovir and acyclovir are highly effective in suppr

30 tity of HSV were detected by PCR between the valacyclovir and acyclovir arms.

31 The efficacy of valacyclovir and acyclovir on genital herpes simplex vir

32 Many of the antivirals discussed, including valacyclovir and cidofovir, have not yet been studied in

33 The role of valacyclovir and CMV HIG in CMV infection in pregnancy i

34 A systematic review on valacyclovir and CMV HIG in preventing vertical transmis

35 Valacyclovir and CMV hyperimmune globulin (HIG) may redu

36 ; however, newer antiviral agents, including valacyclovir and famciclovir, have expanded therapeutic

37 significant difference was found between the valacyclovir and placebo groups.

38 95% confidence interval [CI], 0.01-0.07] for valacyclovir and RR, 0.05 [95% CI, 0.03-0.10] for acyclo

39 r) and PCR (RR, 0.18 [95% CI, 0.12-0.26] for valacyclovir and RR, 0.20 [95% CI, 0.15-0.28] for acyclo

40 orters in complex with the antiviral prodrug valacyclovir and the peptide-based photodynamic therapy

41 elation was found between HSV-1 shedding and valacyclovir and valacyclovir with aspirin treatment.

42 t BPHL may be an important enzyme activating valacyclovir and valganciclovir in humans and an importa

43 ted significant hydrolytic activity for both valacyclovir and valganciclovir with specificity constan

44 specificity of a novel activating enzyme for valacyclovir and valganciclovir.

45 led by high-dose prophylaxis with acyclovir, valacyclovir, and famciclovir.

46 , followed by a 14-day course of the prodrug valacyclovir, and subsequent surgery 1 week later.

47 (10) copies/mL; 95% CI, -.73 to -.30) in the valacyclovir arm than the placebo arm.

48 V-1 level was significantly lower during the valacyclovir arm, compared with the placebo arm (-0.26 l

49 Valacyclovir as a preventive strategy was supported by a

50 Evidence supporting valacyclovir as a treatment strategy was limited to obse

51 s with newly diagnosed ARN treated with oral valacyclovir as the sole antiviral agent.

52 To report the outcome of oral valacyclovir as the sole antiviral therapy for patients

53 Treatment with oral valacyclovir as the sole antiviral therapy resulted in c

54 SV-2-infected (source) partners who received valacyclovir, as compared with 10.8 percent of the days

55 4 of 743 susceptible partners who were given valacyclovir, as compared with 16 of 741 who were given

56 ls/ microL were randomized to receive either valacyclovir at 500 mg twice daily or placebo for 8 week

57 s the risk of transmission, with and without valacyclovir, based on IgG avidity values and MPI timing

58 oacyl esters of acyclovir were designed, and valacyclovir became the successor of acyclovir in the tr

59 The impact of valacyclovir (both groups combined) on each outcome was

60 rials of topical trifluorothymidine and oral valacyclovir but resolved completely with the applicatio

61 AdV-tk plus valacyclovir can be safely delivered with surgery and ac

62 Controlled trials suggest that acyclovir/valacyclovir can provide significant clinical benefits w

63 was not reduced by treatment with 500 mg of valacyclovir daily or with a combination of daily valacy

64 Valacyclovir did not decrease systemic immune activation

65 Valacyclovir did not reduce the number of cervical CD4(+

66 dies suggest that standard-dose acyclovir or valacyclovir does not select for HIV-1 resistance.

67 Valacyclovir enhances acyclovir bioavailability compared

68 Valacyclovir exhibits better oral absorption and higher,

69 n and efficacy of the newly developed agents valacyclovir, famciclovir, cidofovir, oral and intraocul

70 ive pritelivir [corrected] and 46 to receive valacyclovir first when the US Food and Drug Administrat

71 tive AAV patients were randomized to receive valacyclovir for 6 months or no intervention.

72 valacyclovir 1 year (n = 1117); or acyclovir/valacyclovir for at least 1 year or longer if patients r

73 the United States taking daily acyclovir or valacyclovir for between 8 weeks and 24 months.

74 : To compare the efficacy of pritelivir with valacyclovir for suppression of genital HSV-2 infection.

75 cal antiviral, sorivudine, as an adjuvant to valacyclovir for the treatment of acute herpes zoster.

76 placebo group (median, 59 days) than in the valacyclovir group (median, >180 days).

77 days in the pritelivir group vs 3.9% in the valacyclovir group (RR, 0.40; 95% CI, 0.17-0.96; P = .04

78 er of EBV-infected B cells over time for the valacyclovir group versus the control group approached s

79 eeks was 0.07 (95% CI, -0.06 to 0.19) in the valacyclovir group vs -0.04 (95% CI, -0.15 to 0.07) in t

80 was -13.78 (95% CI, -17.00 to -10.56) in the valacyclovir group vs -10.16 (95% CI, -13.37 to -6.96) i

81 SUVR was 0.03 (95% CI, -0.04 to 0.10) in the valacyclovir group vs 0.01 (95% CI, -0.06 to 0.08) in th

82 eatinine level (5 participants [8.3%] in the valacyclovir group vs 2 participants [3.3%] in the place

83 ore was 10.86 (95% CI, 8.80 to 12.91) in the valacyclovir group vs 6.92 (95% CI, 4.88 to 8.97) in the

84 livir group and 69.2% of participants in the valacyclovir group.

85 s (P = 0.62 and P = 0.92 for the control and valacyclovir groups, respectively).

86 cted B cells decreased in subjects receiving valacyclovir (half-life of 11 months; P = 0.02) but not

87 gnificantly higher among patients exposed to valacyclovir (hazard ratio, 3.29 [95% confidence interva

88 fety monitoring data from clinical trials of valacyclovir, involving over 3000 immunocompetent and im

89 Prophylactic treatment with valacyclovir is a safe and effective way to prevent CMV

90 The increased bioavailability of valacyclovir is attributed to carrier-mediated intestina

91 tion of extending the benefits of acyclovir, valacyclovir is now being explored in a number of HSV-re

92 Valacyclovir is proposed to prevent vertical transmissio

93 Valacyclovir is the 5'-valyl ester prodrug of acyclovir,

94 16 percent among seronegative recipients of valacyclovir; it was 6 percent among seropositive placeb

95 Safety profiles of valacyclovir (</=1000 mg/day), acyclovir (800 mg/day), a

96 to the tongue appeared to occur even during valacyclovir-mediated suppression of EBV replication, su

97 Either 4 g/d of valacyclovir (n = 60) or matching placebo (n = 60).

98 ipient or donor) to 3-month prophylaxis with valacyclovir (n=34) or pre-emptive valganciclovir for si

99 on of the effect of the antiviral medication valacyclovir on the symptoms of outpatients with persist

100 d group 3 (n = 16) received a dose of 500 mg valacyclovir once daily and 350 mg aspirin twice daily f

101 andomly assigned to receive either 500 mg of valacyclovir once daily or placebo for eight months.

102 , group 2 (n = 15) received a dose of 500 mg valacyclovir once daily, and group 3 (n = 16) received a

103 can be achieved after administration of oral valacyclovir or intravenous acyclovir.

104 Valacyclovir or matched placebo was given (2 g twice on

105 ed, double-blind trial of twice daily 500 mg valacyclovir or placebo beginning at 34 weeks gestation

106 e randomly assigned to receive either 2 g of valacyclovir or placebo orally four times daily for 90 d

107 lling a prescription for systemic acyclovir, valacyclovir, or famciclovir.

108 costeroids alone, the addition of acyclovir, valacyclovir, or famcyclovir to oral corticosteroids for

109 Thirty participants received 1 g of valacyclovir orally each day for 2 months in a randomize

110 In conclusion, acyclovir/valacyclovir prophylaxis given for 1 year led to a persi

111 In conclusion, compared with valacyclovir prophylaxis, pre-emptive valganciclovir the

112 with 5 years' postmarketing experience with valacyclovir provides evidence of favorable safety and e

113 reatment of HLP and of EBV replication, with valacyclovir, provides new insight into the mechanisms o

114 mong placebo recipients and 26 percent among valacyclovir recipients (P=0.001).

115 of genital herpes at 6 months was 65% among valacyclovir recipients versus 26% among placebo recipie

116 recipients and 1 percent among seropositive valacyclovir recipients.

117 among placebo recipients and 3 percent among valacyclovir recipients.

118 Valacyclovir reduced breast milk HIV-1 RNA detection at

119 Treatment with valacyclovir reduced the incidence or delayed the onset

120 Although valacyclovir reduced the latent viral DNA load better in

121 Daily suppressive therapy with valacyclovir reduces risk of sexual transmission of herp

122 Valacyclovir reduces the frequency of EBV-infected B cel

123 Valacyclovir resulted in a 0.16 (95% confidence interval

124 l HSV-2, the use of pritelivir compared with valacyclovir resulted in a lower percentage of swabs wit

125 for pritelivir and 1.6 per person-month for valacyclovir (RR, 0.80; 95% CI, 0.52 to 1.22; P = .29).

126 Valacyclovir significantly decreased early breast milk a

127 Valacyclovir significantly reduced transmission to 2%, 5

128 Valacyclovir significantly reduces rectal and plasma HIV

129 Once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmiss

130 In time-updated analyses, valacyclovir significantly suppressed the virus load in

131 The valacyclovir structure reveals that prodrug recognition

132 indicating greater cognitive worsening with valacyclovir than placebo (between-group difference, 3.9

133 with significant hydrolytic activity toward valacyclovir, the 5'-glycyl ester of acyclovir, and the

134 vels that could facilitate transmission, and valacyclovir therapy decreases the prevalence of EBV in

135 Short-term valacyclovir therapy did not reverse HSV-2-associated al

136 erpes zoster were randomized to receive oral valacyclovir therapy for 7 days, either 1 g TID or 2 g T

137 The oral dosage schedule of 2 g of valacyclovir TID reaches acyclovir plasma levels similar

138 cterization of a human enzyme that activates valacyclovir to acyclovir.

139 replication were treated with high-dose oral valacyclovir to inhibit productive EBV replication.

140 Valacyclovir to prevent vertical transmission has the hi

141 n was characterized in subjects treated with valacyclovir to suppress EBV replication.

142 ivir treatment vs 3.7 log10 copies/mL during valacyclovir treatment (difference, -0.1; 95% CI, -0.6 t

143 ment compared with 5.3% (392 of 7453) during valacyclovir treatment (relative risk [RR], 0.42 [correc

144 Valacyclovir treatment completely abrogated EBV replicat

145 All patients began 7 days of valacyclovir treatment on day 3.

146 However, valacyclovir treatment resulted in significantly fewer p

147 Valacyclovir treatment suppressed subclinical CMV reacti

148 inations and confusion were more common with valacyclovir treatment, but these events were not severe

149 -infected subjects before, during, and after valacyclovir treatment.

150 rned in normal tongue epithelial cells after valacyclovir treatment.

151 resolved with good functional results after valacyclovir treatment.

152 mozolomide was administered after completing valacyclovir treatment.

153 side derivatives acyclovir, famciclovir, and valacyclovir, treatment of mucocutaneous HSV is a practi

154 ere assigned to placebo (n = 51) or 0.5 g of valacyclovir twice daily (n = 50) for 1 year after initi

155 Suppressive treatment with 0.5 g of valacyclovir twice daily was not shown to prohibit recur

156 nal fluid) were randomized to receive either valacyclovir (VACV) 2 g thrice daily (n = 40) or placebo

157 We treated volunteers with either valacyclovir (valaciclovir) or no antiviral therapy for

158 suppressive therapy using ACV or its prodrug valacyclovir (valACV) reduced plasma HIV-1 viral load (V

159 Acyclovir or valacyclovir was administered in 197 of 205 patients (96

160 r hours after intravitreal injection of HSV, valacyclovir was introduced into the drinking water of t

161 Valacyclovir was not associated with significant changes

162 Valacyclovir was not efficacious with cognitive worsenin

163 Valacyclovir was safe and effective for the suppression

164 Valacyclovir was well tolerated; the incidence of advers

165 Thus, in this study, famciclovir and valacyclovir were equally effective in limiting the viru

166 fficacy for such infections, famciclovir and valacyclovir, were tested in a mouse eye model of HSV in

167 between HSV-1 shedding and valacyclovir and valacyclovir with aspirin treatment.

168 ontrolled trial that compared the effects of valacyclovir with those of acyclovir for CMV disease pre

169 ontrolled trial that compared the effects of valacyclovir with those of acyclovir.

170 ypothesized that prophylactic treatment with valacyclovir would reduce the risk of CMV disease.